Four years of experience with administration of the recombinant factor VIII in children

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F09%3A00100631" target="_blank" >RIV/00843989:_____/09:00100631 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Four years of experience with administration of the recombinant factor VIII in children

Original language description

The safety of therapeutics for haemophilia A patients has improved markedly with the developmentand commercial production of rFVIII products. Currently the most serious and challenging complication is the development of inhibitory antibodies against factor VIII. Risk factors for the development of an inhibitor include: 1. previous exposure to factor VIII replacement products and packed red cells transfusions, 2. severe haemophilia 3. Family history of inhibitors, 4. African ethnicity, 5. Certain mutations of the factor VIII gene, 6. Immune system activation i.e. immunization and 7. early age at first factor replacement therapy.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FG - Paediatrics

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2009

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Hämostaseologie

ISSN

0720-9355

e-ISSN

—

Volume of the periodical

29

Issue of the periodical within the volume

Suppl.1

Country of publishing house

DE - GERMANY

Number of pages

3

Pages from-to

—

UT code for WoS article

000272214600034

EID of the result in the Scopus database

—